Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Thursday 27 May, 2021

Oxford Biomedica PLC

Board Change

RNS Number : 9580Z
Oxford Biomedica PLC
27 May 2021
 

 

Board Change

 

 

Oxford, UK - 27 May, 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, today announces a change to the Group's Board of Directors.

 

 

As announced in the Group's preliminary results, Dr. Andrew Heath will be retiring from the Board as a Non-Executive Director at today's AGM following more than eleven years of service.  Andrew joined the Board in January 2010 and became Deputy Chair and Senior Independent Director in May 2011, stepping down from these roles to that of Non-Executive Director in June 2020.

 

 

Dr. Roch Doliveux,   Non-Executive Chair of Oxford Biomedica, said :

"I would like to thank Andrew for his guidance and wisdom over the past 11 years, where Oxford Biomedica has transformed into a truly life-saving, global leading cell and gene therapy company. His long service to the Group is a true testament to the dedication he has shown over the years and we all wish him well for the future."

 

 

Dr. Andrew Heath said: "It has been an honour and pleasure to serve on the Board of Oxford Biomedica over these past 11 years and assist the Group under the leadership of John Dawson to grow to a global leading FTSE250 company it is today. I wish the whole team much success in the future as the Group continues to grow, improving the lives of many around the world."

 

 

Post the AGM on the 27 May 2021, the members of the Oxford Biomedica Board of Directors will be as follows:

 

Dr. Roch Doliveux, Non-Executive Chairman

 

John Dawson, Chief Executive Officer

 

Stuart Paynter, Chief Financial Officer

 

Stuart Henderson, Deputy Chairman and Senior Independent Director

 

Professor Dame Kay Davies, Independent Non-Executive Director

 

Robert Ghenchev, Non-Executive Director

 

Dr. Heather Preston, Independent Non-Executive Director

 

Dr. Sam Rasty, Independent Non-Executive Director

 

 

 

 

 

-Ends-

 

 

 

 

Enquiries:


 

Oxford Biomedica plc

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Catherine Isted, Head of Corporate Development & IR

 

 

 

 

T: +44 (0)1865 783 000

T: +44 (0)1865 783 000

T: +44 (0)1865 954 161 / E: [email protected]

 

 

Consilium Strategic Communications

 

Mary-Jane Elliott/Matthew Neal

 

 

 

T: +44 (0)20 3709 5700

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at  www.oxb.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEIFAMEFSEII

a d v e r t i s e m e n t